David Scadden Agios Pharmaceuticals, Inc. (AGIO) insider trading activity

AGIO Quotes by TradingView

David Scadden is Director of AGIOS PHARMACEUTICALS, INC.. Currently has a direct ownership of 17,603 shares of AGIO, which is worth approximately $768,370. The most recent transaction as insider was on Nov 12, 2025, when has been sold 200 shares (Common Stock) at a price of $43.84 per share, resulting in proceeds of $8,768. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 17.6K
0% 3M change
13.69% 12M change
Total Value Held $768,370

David Scadden Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 12 2025
SELL
Open market or private sale
$8,768 $43.84 p/Share
200 Reduced 1.12%
17,603 Common Stock
Nov 12 2025
BUY
Exercise of conversion of derivative security
$3,618 $18.09 p/Share
200 Added 1.11%
17,803 Common Stock
Oct 08 2025
SELL
Open market or private sale
$8,200 $41.0 p/Share
200 Reduced 1.12%
17,603 Common Stock
Oct 08 2025
BUY
Exercise of conversion of derivative security
$3,618 $18.09 p/Share
200 Added 1.11%
17,803 Common Stock
Sep 30 2025
SELL
Open market or private sale
$8,000 $40.0 p/Share
200 Reduced 1.12%
17,603 Common Stock
Sep 30 2025
BUY
Exercise of conversion of derivative security
$3,618 $18.09 p/Share
200 Added 1.11%
17,803 Common Stock
Aug 27 2025
SELL
Open market or private sale
$8,000 $40.0 p/Share
200 Reduced 1.12%
17,603 Common Stock
Aug 27 2025
BUY
Exercise of conversion of derivative security
$3,618 $18.09 p/Share
200 Added 1.11%
17,803 Common Stock
Jul 10 2025
SELL
Open market or private sale
$56,000 $40.0 p/Share
1,400 Reduced 7.37%
17,603 Common Stock
Jul 10 2025
BUY
Exercise of conversion of derivative security
$25,326 $18.09 p/Share
1,400 Added 6.86%
19,003 Common Stock
Jun 20 2025
BUY
Exercise of conversion of derivative security
-
2,120 Added 10.75%
17,603 Common Stock
Dec 11 2024
SELL
Open market or private sale
$9,256 $46.28 p/Share
200 Reduced 1.28%
15,483 Common Stock
Dec 11 2024
BUY
Exercise of conversion of derivative security
$3,618 $18.09 p/Share
200 Added 1.26%
15,683 Common Stock
Jun 13 2024
BUY
Exercise of conversion of derivative security
-
3,388 Added 17.95%
15,483 Common Stock
Jun 21 2023
BUY
Exercise of conversion of derivative security
-
4,975 Added 29.14%
12,095 Common Stock
May 20 2022
BUY
Exercise of conversion of derivative security
-
1,585 Added 18.21%
7,120 Common Stock
May 28 2021
BUY
Exercise of conversion of derivative security
-
1,686 Added 23.35%
5,535 Common Stock

Also insider at

MGTA
Magenta Therapeutics, Inc. Healthcare
Director
EDIT
Editas Medicine, Inc. Healthcare
Director
SESN
Sesen Bio, Inc. Healthcare
Director
DS

David Scadden

Director
Cambridge, MA

Track Institutional and Insider Activities on AGIO

Follow AGIOS PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AGIO shares.

Notify only if

Insider Trading

Get notified when an Agios Pharmaceuticals, Inc. insider buys or sells AGIO shares.

Notify only if

News

Receive news related to AGIOS PHARMACEUTICALS, INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on AGIO